ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The Company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The Company also provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide.
äŒæ¥ã³ãŒãCLPT
äŒç€ŸåClearpoint Neuro Inc
äžå Žæ¥Jul 03, 2019
æé«çµå¶è²¬ä»»è
ãCEOãBurnett (Joseph Michael)
åŸæ¥å¡æ°115
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jul 03
æ¬ç€Ÿæåšå°120 S. Sierra Avenue
éœåžSOLANA BEACH
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·92075
é»è©±çªå·19499006833
ãŠã§ããµã€ãhttps://www.clearpointneuro.com/
äŒæ¥ã³ãŒãCLPT
äžå Žæ¥Jul 03, 2019
æé«çµå¶è²¬ä»»è
ãCEOãBurnett (Joseph Michael)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã